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CASE REPORT
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review
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ABSTRACT

ARTICLE HISTORY

Acute Generalized Exanthematous Pustulosis (AGEP) is a rare drug reaction manifesting as
pustular lesions with surrounding erythema following exposure. The disease is often selflimited and treatment is supportive. It may present in an atypical variant with vesicles that
desquamate into erosions, which classifies the disease as an AGEP/SJS Overlap. This overlap
syndrome can carry a substantial mortality rate and necessitate elevation in the level of care.
Hydroxychloroquine has been implicated in cases of AGEP, and we present a case of AGEP/
SJS overlap attributed to this common medication. Given the prevalence of drug eruptions, it
is critical for the physicians to recognize and not overlook this rare and potentially fatal
dermatological emergency.
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1. Introduction
Dermatological eruptions are among the most common complications a clinician manages when prescribing treatments to patients, and have been
reported to occur in as many a 3–16% of all hospitalized patients [1,2]. These eruptions are known to
occur with frequently prescribed medications, and
often resolve following withdrawal of the offending
agent. Severe eruptions, including certain dermatological emergencies, are far rarer. Two such conditions,
Stevens – Johnson syndrome (SJS) and Toxic
Epidermal Necrolysis (TEN), are well known among
clinicians. A lesser known one, Acute Generalized
Exanthematous Pustolosis (AGEP), is equally important for the internist to recognize as it may follow
a course similar to that of SJS or TEN, in a syndrome
termed ‘AGEP Overlap’ [3].

2. Case scenario
A 71-year-old woman with a past medical history of
rheumatoid factor-negative arthritis presented to the
emergency room with a three-day history of
a pustular rash, fourteen days after starting
Hydroxychloroquine. It began on her upper chest,
and quickly spread to cover her entire chest, abdomen, back, shoulders, neck, scalp and under bilateral
breasts. The lesions were intensely pruritic and with
scale, but without odor, blood, or drainage. Skin in
the breast folds was excoriated and tender. The
patient denied any changes in her diet, detergents or
soaps, as well as recent travel, sick contacts or
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exposures to animals, ticks or other vectors. She had
no history of drug reactions, environmental allergies
or history of anaphylaxis.
Physical Examination demonstrated widespread
erythroderma with pustular and scaling lesions across
her chest (Figure 1), back, shoulders (Figure 2), upper
extremities, neck (Figure 3) and head. Sloughing and
excoriations under her bilateral breasts (Figure 4) and
lesions involving her hard palate were also noted.
Non-blanching purpura were noted on her bilateral
lower extremities (Figure 5). The total estimated
involved body surface area was near thirty percent,
however, estimated surface area with desquamation
was around one percent. Her vital signs were stable
and she was afebrile. She had no signs of respiratory
distress, no audible stridor and no tongue swelling.
Laboratory investigations demonstrated leukocytosis
with a WBC of 20.8 10E3/uL and Eosinophilia with
a count of 1.86 10E3/uL. The patient was initially
treated for suspected AGEP with supportive measures
including intravenous fluid resuscitation and inpatient medical-surgical ward nursing care. Her
Hydroxychloroquine was discontinued. Within
12 hours, the rash expanded to include larger areas
of sloughing, and expansive palate lesions. Her vitals
remained stable throughout this evolution. This
changed prompted intravenous corticosteroids and
anti-histamines. With progressive sloughing and
mucous membrane sensitivity, the patient was transferred to the regional inpatient burn care unit. There,
punch biopsy revealed ‘neutrophilic pustule formation with mild acantholysis, basilar epidermal
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Figure 1. Right chest.
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Figure 5. Right thigh.

spongiosis, rare dyskeratotic keratinocytes, superficial
dermal perivascular chronic inflammation with neutrophils and rare eosinophils, and mild papillary dermal edema suggestive of AGEP.’ She was treated for
a total of ten days in the burn unit, and survived to
discharge. At a six-month interval follow-up, she had
no long term sequelae, and remained off of
Hydroxychloroquine.

3. Discussion

Figure 2. Right shoulder.

Figure 3. Right neck.

Figure 4. Under bilateral breasts.

AGEP is a rare dermatological drug eruption that
typically presents with the rapid development of
innumerable, non-follicular pustules overlying widespread erythroderma, and rapidly spreads in a diffuse
or patchy distribution [4,5]. This drug reaction tends
to occur soon after administration of an offending
agent, often one day after a culprit antibiotic or
eleven days after drugs of other classes [6]. AGEP in
association
with
administration
of
Hydroxychloroquine has been infrequently reported
in the literature, with a total of twenty-one cases
following a PubMed search using the terms
‘Hydroxychloroquine’ and ‘Pustolosis.’ Typically,
this disease process is self-limited and requires basic
supportive measures [7–9]. Rarely, AGEP can present
in an atypical fashion with the development of blisters and vesicles that can coalesce, desquamate and
form superficial erosions in an AGEP/SJS Overlap
Syndrome [3,10,11]. This overlap syndrome can follow a course similar to that seen with SJS/TEN, which
includes severe fluid loss, thermal dysregulation and
secondary skin infections [12].
SJS and TEN are two entities on a spectrum of
presentations of the same disease process, and are the
two most well-known, highly mortal dermatological
emergencies. These drug reactions are characterized
by extensive epidermal sloughing and necrosis, with
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SJS involving less than 10% of total BSA and TEN
involving greater than 30% [13,14]. The mortality
associated with SJS and TEN are also on
a continuum, with typical mortality rates approaching 10% to 30%, respectively [15,16]. Treatment typically involves aggressive supportive care including
fluid and electrolyte repletion, temperature management, pain control and prevention of secondary skin
infections. This is typically accomplished in burn care
unit.

4. Conclusion
AGEP Overlap is a complicated and rare dermatological
drug eruption that follows a course similar to that of SJS
and TEN. Because of the complications that arise with
these atypical lesions, the mortality associated with
AGEP Overlap Syndrome can be as high as 5%, which
is similar to the mortality rates seen in SJS [17].
Treatment parallels that of SJS/TEN, and transfer to
a burn care unit may improve morbidity and mortality
[18]. Given the frequency of drug eruptions, along with
the implied morbidity and mortality of this condition,
clinicians must promptly recognize and initiate treatment for an AGEP Overlap Syndrome, particularly in
patients newly started on Hydroxychloroquine.
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